<DOC>
	<DOCNO>NCT00267969</DOCNO>
	<brief_summary>The primary purpose study evaluate effectiveness safety ustekinumab ( CNTO 1275 ) treatment patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>A Study Safety Effectiveness Ustekinumab ( CNTO 1275 ) Patients With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This randomize ( patient assign different treatment base chance ) , double blind ( neither patient physician know whether medication placebo [ inactive substance compare medication test whether medication real effect clinical study ] take , dosage ) , parallel-group ( group patient treat time ) , multicenter study determine effectiveness safety two different dos ustekinumab administer subcutaneously ( skin ) compare placebo patient moderate severe plaque-type psoriasis ( common type psoriasis ) . 766 patient randomize Group 1 ( ustekinumab 45 mg ) , Group 2 ( ustekinumab 90 mg ) Group 3 ( placebo ) Week 0 . The study design evaluate effectiveness safety 2 dose regimen ustekinumab : ( 1 ) 45 mg Weeks 0 4 follow 45 mg every 12 week maintenance therapy ( treatment design help original primary treatment succeed ) ( 2 ) 90 mg Weeks 0 4 follow 90 mg every 12 week maintenance therapy . The study consist 4 period : ( 1 ) Placebo-controlled portion study [ Week 0 Week 12 ] safety effectiveness 2 dos ( 45mg 90mg ) ustekinumab compare placebo ; ( 2 ) Placebo crossover active treatment portion study [ Week 12 Week 40 ] patient randomize receive placebo Week 0 crossover receive ustekinumab , patient receive active treatment ; ( 3 ) Randomized withdrawal portion study [ begin Week 40 ] patient receive ustekinumab [ 45mg 90mg every 12 week ] Week 0 responding , randomize either placebo continued maintenance therapy ustekinumab ; ( 4 ) Long-term extension [ Week 52 Week 264 ( ie , 5 year ) ] period safety effectiveness ustekinumab long-term use evaluate patient .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Patients plaquetype psoriasis diagnose least 6 month prior cover least 10 % total body surface area Have psoriasis areaandseverity index score &gt; =12 Patients consider treat dermatologist candidate phototherapy systemic treatment psoriasis Have history latent active TB Currently nonplaque form psoriasis druginduced psoriasis Have therapeutic agent target reduce IL12 IL23 Have BCG vaccination within previous 12 month Have history chronic recurrent infectious disease serious infection require hospitalization intravenous antibiotic within previous 2 month Have ever nontuberculous mycobacterial infection opportunistic infection Patients know infected human immunodeficiency virus , hepatitis B , hepatitis C Have current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Patients malignancy history malignancy ( exception certain skin cancer preinvasive cervical cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Ustekinumab</keyword>
	<keyword>CNTO1275</keyword>
	<keyword>Plaque type Psoriasis</keyword>
	<keyword>Interleukin-23</keyword>
	<keyword>IL-23</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Interleukin 12</keyword>
	<keyword>IL-12</keyword>
</DOC>